The tumor suppressor phosphatase PTEN regulates cell migration, growth and survival by dephosphorylating phosphatidylinositol second messengers and signaling phosphoproteins. PTEN possesses a C-terminal non-catalytic regulatory domain that contains multiple putative phosphorylation sites, which could play an important role in the control of its biological activity. The protein kinase CK2 phosphorylated, in a constitutive manner, a cluster of Ser/Thr residues located at the PTEN C-terminus.
INTRODUCTION
The tumor suppressor gene PTEN (also named as MMAC1 or TEP-1) (1-3) encodes a phosphatase with enzymatic activity towards both protein substrates and the lipid second messenger, phosphatidylinositol-3,4,5-triphosphate (PIP3) (4) (5) (6) . PTEN regulates distinct signal transduction pathways, including the PI3K/PKB cell survival-and the integrin-triggered signaling pathways (for recent reviews, see ref. [7] [8] [9] [10] . Structurally, PTEN protein is composed of a N-terminal dual specificity phosphatase-like enzyme domain, and a C-terminal regulatory domain, which binds to phospholipid membranes (11) . Mutations in PTEN gene are present in a wide number of tumors, as well as in the germline cells of patients with several inherited cancer syndromes (reviewed in ref. 12, 13) . The importance of PTEN catalytic activity in its tumor suppressor function is underscored by the fact that the majority of PTEN missense mutations detected in tumor specimens, target the phosphatase domain and cause a loss in PTEN phosphatase activity. In addition, a large number of PTEN nonsense or frameshift mutations found in tumors, are targeted to the C-terminal domain of the protein, suggesting an important role for this domain in the regulation of the PTEN tumor suppressor activity. At this regard, the C-terminal region of PTEN has been shown to be important in the regulation of the stability and half-life of the molecule (14, 15) . Also, the C-terminal PTEN amino acid sequence possesses a putative PDZ binding motif, which has been proposed to modulate PTEN functions by association to PDZ domain-containing proteins (16) (17) (18) (19) .
Finally, the C-terminal PTEN domain is rich in putative phosphorylation sites, and phosphorylation of the PTEN C-terminus has been recently reported to affect PTEN protein stability and function (20) ; however, the kinase responsible of such phosphorylation remains unidentified.
Protein kinase CK2 (formerly casein kinase II) is a highly conserved, ubiquitously expressed, messengerindependent serine/threonine-kinase that phosphorylates a wide variety of substrates involved in essential cell processes, including cell cycle and cell growth (21) (22) (23) . In mammals, CK2 is a heterotetramer in vivo, composed of two catalytic (α and/or α) and two regulatory (β) subunits. Alterations in CK2 expression have been found in distinct types of tumors (24) (25) (26) , and overexpression of the catalytic or regulatory CK2 subunits differentially affects cell growth and transformation (27) (28) (29) (30) (31) . Also, antibody-mediated CK2 depletion inhibited cell cycle progression and growth of fibroblasts (32) , and CK2 antisense oligonucleotide treatment blocked neurite outgrowth in neuroblastoma cells (33) .
In this report, we demonstrate that the C-terminus of the tumor suppressor PTEN is constitutively phosphorylated by CK2, at several residues, in intact cells. An insight is provided on the putative role of phosphorylation as a regulatory mechanism of PTEN biological activity, by modulating its stability to proteasome-mediated degradation.
MATERIALS AND METHODS

Plasmids, antibodies and reagents.
The cDNA encoding full length human PTEN was obtained by RT-PCR amplification of poly-A+ mRNA from MCF-7 cells, using primers flanking the human PTEN coding region (1-3), and PTEN nucleotide sequence was confirmed by DNA sequencing. pRK5 mammalian expression vectors were made by PCR amplification of PTEN or GST cDNAs and subcloning. For the construction of bacteria expression plasmids encoding GST-PTEN fusion proteins, PTEN cDNAs were cloned into the pGEX-4T1 or pGEX-5X1 expression vectors. PTEN C-terminus truncation mutants and amino acid substitution mutants were made by PCR oligonucleotide site-directed mutagenesis, and mutations were confirmed by DNA sequencing. The 12CA5 anti-HA and the 4G10 anti-phosphotyrosine mAb have been previously described (34) . The rabbit polyclonal anti-PTEN CS486 and BT166 antibodies were from R. Parsons and C. Eng, respectively (35, 36) . The anti-GST mAb (clone 22.A) was obtained in our laboratory and is directed against S. japonicum GST. Horseradish peroxidase conjugated goat antimouse secondary antibody was from Promega (Madison, WI.). Activating agents were used as follows: PMA (Sigma Chemical Co., St Louis, MO), 10 ng/ml, 30 min; EGF (Gibco-BRL, Gaithersburg, MD), 50 ng/ml, 10 min; insulin (Sigma Chemical Co.), 1 µg/ml, 10 min; okadaic acid (Boehringer Mannheim, Mannheim, Germany), 1 µM, 30 min; sodium pervanadate (Sigma Chemical Co.), 10 µM, 30 min; A23187 calcium ionophore (Boehringer Mannheim), 10 µM, 30 min; All incubations were made at 37º C. Human recombinant CK2 holoenzime was from Boehringer Mannheim. CK2 modulators were used as follows: spermine (Sigma Chemical Co.), 1 mM; heparine (Sigma Chemical Co.), 1 µg/µl; 5,6-Dichloro-1-β-D-ribofuranosyl-benzimidazole (DRB) (BIOMOL Research Laboratories Inc., Plymouth Meeting, PA), 100 µM. The MEK1/2 inhibitor PD98059 (New England Biolabs Inc., Beverly, MA) was used at 10 µM, and dibutyryl cAMP (Boehringer Mannheim) was used at 50 µM. The proteasome inhibitor MG132 (Peptide Institute Inc., Osaka, Japan) was used at 50 µM, leupeptin (Peptide Institute Inc.) was used at 0.1 mM, and NH 4 Cl was used at 20 mM. 
RESULTS
PTEN is a phosphoprotein under standard cell growth conditions.
To study the putative role of posttranslational modifications in the regulation of PTEN biological functions, the possibility was investigated that PTEN could be phosphorylated in intact cells. MCF-7 cells, known to carry a wild type PTEN gene (1),
were labeled with 32 P, and cell lysates were subjected to immunoprecipitation using two distinct anti-PTEN antibodies ( Fig 1A) . As shown, both anti-PTEN antibodies immunoprecipitated a radiolabeled protein that migrated at about 55 kDa ( To ascertain the identity of the kinase(s) involved in the phosphorylation of PTEN, 32 P-labeled COS-7 cells were transfected with HA-PTEN and incubated in the presence of stimulators of several signal transduction pathways, including okadaic acid, sodium pervanadate, A23187 calcium ionophore, insulin, PMA, and EGF. As shown, none of these stimuli significantly modified the phosphorylation level of HA-PTEN ( Fig. 2A,   lanes 1-7) . We also tested the possibility that PTEN could be phosphorylated on tyrosine residues. For these experiments, a GST-PTEN fusion protein was overexpressed in COS-7 cells, precipitated in one-step using glutathione-Sheparose, and subjected to immunoblot with the anti-phosphotyrosine 4G10 mAb (Fig 2B) . No reactivity of the 4G10 mAb towards GST-PTEN was detected ( 
PTEN is phosphorylated by CK2 both in vitro and in vivo
The above results suggest that a messenger-independent serine/threonine kinase may phosphorylate PTEN in intact cells. Residues 369-386 of PTEN amino acid sequence include several consensus phosphorylation sites for protein kinase CK2
[S/TXXD/E/S(P)/T(P)] (residues Ser370, Ser380, Thr382, Thr383, and Ser385; see Fig. 3B ), which is known to phosphorylate in vivo, in a constitutive manner, a wide array of substrates (23) . Thus, the possibility was tested that PTEN could be phosphorylated by CK2. First, in vitro CK2 kinase assays were performed, using bacteria-purified GST-PTEN molecules (wild type or truncated forms) as substrates, and purified CK2 as the kinase. Both, GST-PTEN 1-403 and GST-PTEN 202-403 (full length and C-terminal domain of PTEN, respectively) were strongly phosphorylated by CK2 (Fig. 3A, lanes 2 and 4, respectively), whereas this kinase did not phosphorylate GST alone or GST-PTEN 1-202 (N-terminal domain of PTEN) (Fig. 3A, lanes 1 and 3, respectively) .
Furthermore, the C-terminal truncated GST-PTEN 1-386, but not the GST-PTEN 1-369, was also phosphorylated by CK2 (Fig. 3A , lanes 6 and 7, respectively). Next, amino acid substitution mutants were generated that replaced to Ala the CK2 putative phosphorylation sites within the 369-386 PTEN region, and the mutant GST-PTEN 1-
403 fusion proteins were also tested for in vitro phosphorylation by CK2. As shown in GST-PTEN 1-202 or GST alone were not (Fig. 3C , lane 1; and data not shown).
Remarkably, this phosphorylation was substantially increased in the presence of spermine, an activator of CK2 (Fig. 3C) . On the other hand, in the presence of any of two CK2 inhibitors, DRB or heparin, the phosphorylation of GST-PTEN was inhibited ( PTEN phosphorylation was also analyzed on 32 P-labeled COS-7 cells overexpressing the distinct HA-PTEN CK2 phosphorylation mutants (Fig. 4) . A significant reduction in the in vivo PTEN phosphorylation was observed on the S370A and S385A mutants (Fig. 4 , upper panel, lanes 2 and 6, respectively). Also, a consistently reduced labeling was observed on the S380A mutant (Fig. 4, upper panel, lane 3) , whereas the effect on the phosphorylation of the individual T382A or T383A mutants was less manifest (Fig.   4 , upper panel, lanes 4 and 5, respectively). Since these results suggested the involving of multiple residues on PTEN phosphorylation in intact cells, combined mutations were generated and tested for in vivo phosphorylation. The phosphorylation of the double mutant S370A/S385A (DMA) was nearly absent (Fig. 4, upper panel, lanes 8 and 12) , and the phosphorylation of the triple mutant S380A/T382A/T383A (TMA) was markedly decreased (Fig 4, upper panel, lane 11) , indicating an additive contribution of all these residues to PTEN phosphorylation in intact cells. The phosphorylation of a double phosphomimetic S370E/S385E (DME) mutant was also analyzed. As shown, the S370E/S385E mutant was hyperphosphorylated in comparison with the S370A/S385A mutant (Fig. 4 , upper panel, lane 13), suggesting that phosphorylation of these two PTEN residues might prime for additional phosphorylation of nearby residues. Finally, the putative in vivo phosphorylation of the Thr401 residue, located within the PDZ binding-consensus motif of PTEN, was also tested. As shown, the phosphorylation level of the T401A mutant was almost indistinguishable to the wild type PTEN (Fig. 4, upper panel, lane 7). Together, these results support the notion that CK2 constitutively phosphorylates in COS-7 cells a cluster of Ser/Thr residues at the C-terminus of PTEN.
Phosphorylation of PTEN C-terminus is important for PTEN protein stability to proteasome-mediated degradation
To analyze the effect of PTEN phosphorylation on the stability of the molecule, pulsechase experiments were performed on [ 35 S]methionine-labeled COS-7 cells, transfected with HA-PTEN wild type or phosphorylation mutants. The kinetics of degradation of HA-PTEN wild type was 2 to 3 times slower than that showed by the distinct Ser/Thr to Ala phosphorylation mutants (Fig 5A) . Comparative plots of degradation of wild type PTEN with the S370A, T380A, T382A, T383A, S385A and S370A/S385A (DMA) mutants are shown (Fig. 5A) . These results suggested that the presence of the phosphorylated residues could be important for PTEN stability. To test this possibility, the degradation of the phosphomimetic S370E/S285E (DME) mutant was analyzed. Interestingly, the stability of the S370E/S385E mutant was almost identical to that obtained with the wild type PTEN (Fig. 5A, right panel) , reinforcing the hypothesis of a role of phosphorylation of PTEN in protein stabilization.
To ascertain the degradative pathway of PTEN under these conditions, transfected COS-7 cells were pulsed with [ 35 S]methionine, and chases were performed in the presence of the proteasome inhibitor MG132 or the lysosome inhibitors leupeptin + NH 4 Cl. As shown, the proteasome inhibitor MG132 inhibited the degradation of both PTEN wild type and S370A/S385A mutant (Fig. 5B, lanes 3 and 7) , whereas no inhibition was observed in the presence of leupeptin + NH 4 Cl (Fig. 5B, lanes 4 and 8) . (Fig 5C, lanes 3) . Together, these results indicate that defective PTEN phosphorylation by CK2 accelerates the proteasome-mediated degradation of PTEN.
DISCUSSION
On the basis that many CK2 substrates are oncogene products or tumor suppressor proteins, as well as key signal transduction proteins, a role for CK2 in the regulation of cell growth-and cell cycle-related processes has been proposed (22, 23) . In this report, we provide evidence that the tumor suppressor phosphatase PTEN is phosphorylated by CK2, both in vitro and in intact cells. CK2-phosphorylation sites in PTEN were located within a C-terminal cluster of Ser/Thr residues, which were found to be important for PTEN stability to proteasome-mediated degradation. The CK2 phosphorylation sites were identified as the PTEN residues Ser370, Ser380, Thr382, Thr383 and Ser385.
Since some of these sites can be generated after previous phosphorylation of nearby residues, and the phosphomimetic S370E/S385E mutant is phosphorylated more efficiently than the S370A/S385A mutant, hierarchic CK2-multisite phosphorylation of this region of PTEN is likely to exist (37) . Several findings support the notion that CK2
is the major kinase involved in the phosphorylation of PTEN in intact cells. We have found that PTEN suffers a rapid degradation in COS-7 cells, which was inhibited by the proteasome inhibitor MG132, but not by lysosome inhibitors, indicating that the turnover of PTEN in cultured COS-7 cells mainly depends on proteasomemediated degradation. The involving of the proteasome in the degradation and regulation of the functions of short-lived proteins, including oncoproteins, tumor suppressors and cell cycle proteins, has been extensively described (for reviews, see ref.
38-40). Thus, regulated degradation of PTEN via the proteasome could be envisaged as a major physiological mechanism that controls the amount of PTEN in specific cell types and tissues. In this context, it has been recently reported that C-terminal truncation mutants of PTEN have a shorter half-life than the wild type molecule (14, 15) . In addition, we show that Ser/Thr to Ala amino acid mutations at the PTEN Cterminus, leading to defective phosphorylation by CK2, accelerate the proteasome-mediated degradation of PTEN; however, a double Ser to Glu mutation (S370E/S385E mutant), that mimicked constitutive CK2 phosphorylation of PTEN at these sites, showed a degradation rate comparable to the wild type molecule. bands were excised from the gel and counted in a scintillation counter, or were analyzed using a phosphor-Imager.
